Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial
Posted inInfectious Diseases news Respiratory

Delpazolid Emerges as a Safer Oxazolidinone Alternative for Tuberculosis: Results from the PanACEA-DECODE-01 Trial

The Phase 2b PanACEA-DECODE-01 trial identifies delpazolid 1200 mg once daily as an effective and safer oxazolidinone alternative to linezolid, demonstrating a 38% faster mycobacterial load decline when added to a bedaquiline, delamanid, and moxifloxacin backbone for pulmonary tuberculosis treatment.
Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial
Posted inInfectious Diseases news Respiratory

Sutezolid Enhances Bactericidal Activity Without Class-Specific Toxicities: Insights from the PanACEA-SUDOCU-01 Trial

The Phase 2b PanACEA-SUDOCU-01 trial demonstrates that sutezolid significantly increases the bactericidal activity of a bedaquiline-delamanid-moxifloxacin regimen in pulmonary tuberculosis, notably without the neuropathy or myelosuppression typical of linezolid, offering a promising alternative for drug-resistant TB therapy.
Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)
Posted inInfectious Diseases news Respiratory

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)

The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse events and worse 65‑week composite clinical outcomes, leading to early termination.